Ebola vaccine trial

Ebola vaccine trial

C021/7849 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 25.0MB

Downloadable file size: 4.1MB

Price image Pricing

Please login to use the price calculator


This image is part of the feature B B C

Credit: NATIONAL INSTITUTES OF HEALTH/SCIENCE PHOTO LIBRARY

Caption: Ebola vaccine trial. Man receiving a dose of the investigational NIAID/GSK ebola vaccine. This trial will determine if the vaccine is safe in humans and if it induces an adequate immune response. The vaccine uses a chimpanzee cold virus (chimp adenovirus type 3) to carry segments of genetic material from two ebola viruses. The viruses cause ebola virus disease (EVD), a severe and often fatal disease with symptoms including fever, fatigue, muscle aches, vomiting, diarrhoea and haemorrhaging (internal bleeding). It is spread through direct contact with infected bodily fluids. There is no cure for the disease, but three quarters of patients can recover if provided with sufficient medical support. Photographed at the NIH Clinical Center, Bethesda, Maryland, USA, on 4th September 2014.

Release details: Model release not required. Property release not required.

Keywords: 2014 outbreak, adult, american, arm, bethesda, bivalent vaccine, chimp adenovirus type 3, deady, ebola haemorrhagic fever, ebola hemorrhagic fever, ebola virus, ebola virus disease, ehf, epidemic, evd, fatal, human, human body, immunisation, immunising, immunization, immunology, injecting, inoculating, inoculation, investigational, male, man, maryland, medical, medicine, niaid/gsk ebola vaccine, nih clinical center, north america, people, person, pharmacological, pharmacology, phase 1 clinical trial, protection, protective, public health emergency, syringe, trial, united states, usa, vaccinating, vaccination, vaccine, viral, volunteer, vrc 207, western africa

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.